54917
(R)-2-ヒドロキシ酪酸
≥97.0% (T)
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C4H8O3
CAS番号:
分子量:
104.10
UNSPSC Code:
51113400
NACRES:
NA.22
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
1720939
製品名
(R)-2-ヒドロキシ酪酸, ≥97.0% (T)
InChI key
AFENDNXGAFYKQO-GSVOUGTGSA-N
SMILES string
CC[C@@H](O)C(O)=O
InChI
1S/C4H8O3/c1-2-3(5)4(6)7/h3,5H,2H2,1H3,(H,6,7)/t3-/m1/s1
assay
≥97.0% (T)
form
solid
optical purity
enantiomeric ratio: ≥99:1 (GC)
mp
50-54 °C
functional group
carboxylic acid
hydroxyl
storage temp.
2-8°C
Quality Level
関連するカテゴリー
Other Notes
キラルなビルディングブロック。
signalword
Danger
hcodes
Hazard Classifications
Eye Dam. 1 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
K.J. Hale et al.
Tetrahedron Letters, 36, 6965-6965 (1995)
M N Romanelli et al.
Chirality, 8(8), 579-584 (1996-01-01)
The enantiomers of 3-alpha-tropyl 2-(phenylthio)butyrate (SM32, 1) were prepared by chiral synthesis and tested for analgesic, cognition-enhancing, and ACh-releasing properties. They show enantioselectivity in some of the tests, the eutomer being related in configuration to R-(+)-hyoscyamine.
M N Romanelli et al.
Chirality, 8(3), 225-233 (1996-01-01)
The enantiomers of two alpha-tropanyl esters, SM21 (1) and PG9 (2), derived from (+)-R-hyoscyamine, that act by increasing the central cholinergic tone, were obtained by esterification after resolution of the corresponding racemic acids [(-)-S-1, (-)-R-2 and (+)-S-2] and by stereospecific
Si Jae Park et al.
Applied microbiology and biotechnology, 93(1), 273-283 (2011-08-16)
We have previously reported in vivo biosynthesis of polylactic acid (PLA) and poly(3-hydroxybutyrate-co-lactate) [P(3HB-co-LA)] employing metabolically engineered Escherichia coli strains by the introduction of evolved Clostridium propionicum propionyl-CoA transferase (Pct(Cp)) and Pseudomonas sp. MBEL 6-19 polyhydroxyalkanoate (PHA) synthase 1 (PhaC1(Ps6-19)).
Philip J Saylor et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 18(13), 3677-3685 (2012-05-17)
Androgen deprivation therapy (ADT) for prostate cancer causes an increase in fasting insulin and adverse changes in body composition and serum lipid profile. It is unknown what other metabolic alterations are caused by ADT. To better characterize the metabolic effects
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）